Deciphera Pharmaceuticals, Inc. (DCPH) financial statements (2021 and earlier)

Company profile

Business Address 200 SMITH STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments136120294197
Cash and cash equivalents136120294197
Receivables14   
Inventory, net of allowances, customer advances and progress billings6   
Inventory6   
Other undisclosed current assets42947371
Total current assets:584593301198
Noncurrent Assets
Operating lease, right-of-use asset3621
Property, plant and equipment106131
Long-term investments and receivables9   
Long-term investments9   
Restricted cash and investments321 
Other noncurrent assets   0
Total noncurrent assets:5829151
TOTAL ASSETS:642622316199
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities33382314
Accounts payable122084
Accrued liabilities45149
Employee-related liabilities1713  
Debt 2  
Due to related parties  00
Other undisclosed current liabilities3720  
Total current liabilities:70602314
Noncurrent Liabilities
Long-term debt and lease obligation2916  
Operating lease, liability2916
Liabilities, other than long-term debt  11
Due to related parties  11
Other liabilities  00
Other undisclosed noncurrent liabilities(29) 11 
Total noncurrent liabilities:2916131
Total liabilities:99763615
Stockholders' equity
Stockholders' equity attributable to parent, including:544546280184
Common stock110 
Additional paid in capital1,2981,034575380
Accumulated other comprehensive income00  
Accumulated deficit(754)(488)(296)(196)
Other undisclosed stockholders' equity attributable to parent   0
Total stockholders' equity:544546280184
TOTAL LIABILITIES AND EQUITY:642622316199

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues4225  
Cost of revenue(0)   
Cost of goods and services sold(0)   
Gross profit:4225  
Operating expenses(313)(226)(104)(51)
Operating loss:(271)(201)(104)(51)
Nonoperating income5841
Other nonoperating income5941
Interest and debt expense (0)(0)(0)
Loss before gain (loss) on sale of properties:(266)(192)(100)(50)
Other undisclosed net income 00 
Net loss:(266)(192)(100)(50)
Other undisclosed net income attributable to parent   0
Net loss available to common stockholders, diluted:(266)(192)(100)(50)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(266)(192)(100)(50)
Comprehensive loss:(266)(192)(100)(50)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0  
Comprehensive loss, net of tax, attributable to parent:(267)(192)(100)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: